IP Library Granted Patent US 8,088,590
Granted Patent B2
US 8,088,590 · App. 11/646,706 · Granted Jan 3, 2012

Use of FOXC2 in diagnosing, preventing and treating cancer metastasis

Assignee: Whiteland Institute for Biomedical Research
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,088,590
App. No.
11/646,706
Granted
Jan 3, 2012
Kind
B2
Abstract

The invention relates to methods and compositions for inhibiting metastasis, such as by inhibiting FOXC2 expression or activity. The invention further relates to methods of prognosticating, diagnosing, and assisting in the diagnosis of metastasis in an individual, or of determining the metastatic potential of a tumor. The invention further relates to methods of identifying agents which inhibit metastasis.

Claims (12)

1. A method for predicting the likelihood that the tumor in an individual will metastasize, the method comprising

(a) determining the level of a Forkhead Box C2 (FOXC2) gene product in a sample obtained from the tumor of the individual; and

(b) comparing the level with a control level of FOXC2 expression from a non-metastatic tumor sample,

wherein if the level determined in (a) is greater than the control level, the individual is said to have increased likelihood of the tumor metastasizing.

2. A method of predicting the likelihood of development of a tumor metastasis in an individual, comprising the steps of:

(a) obtaining a tumor sample from the individual to be tested;

(b) determining the level of a Forkhead Box C2 (FOXC2) gene product in the tumor sample; and

(c) comparing the level determined in (b) with a control level of FOXC2 expression from a non-metastatic tumor sample,

wherein if the level determined in (b) is greater than the control level, then the individual has an increased likelihood of developing a metastatic condition.

3. The method of claim 2 , wherein the FOXC2 gene product is a FOXC2 polypeptide or a FOXC2 mRNA.

4. The method of claim 2 , wherein determining the level of the FOXC2 gene product in the biological sample comprises determining the bioactivity of a FOXC2 polypeptide in the sample.

5. The method of claim 2 , further comprising determining the level of at least one additional gene product in the sample that is indicative of metastasis.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 13, 2011
From: WHITEHEAD INSTITUTE FOR BIOMEDICAL RES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027371/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2011
From: MANI, SENDURAI; YANG, JING; WEINBERG, ROBERT A.
To: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
Reel/Frame 027017/0770 →
Continuity (3)
Continuation 11090437 · Mar 25, 2005
Provisional Application 60556726 · Mar 26, 2004
Related Publication 20100260827A1 · Oct 14, 2010